Invesco’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.13B | Sell |
3,754,318
-320,802
| -8% | -$96.8M | 0.09% | 162 |
|
|
2026
Q1 | $1.35B | Sell |
4,075,120
-1,058,863
| -21% | -$360M | 0.13% | 126 |
|
|
2025
Q4 | $2.04B | Buy |
5,133,983
+3,652,141
| +246% | +$1.62B | 0.19% | 83 |
|
|
2025
Q3 | $676M | Buy |
1,481,842
+140,148
| +10% | +$57.1M | 0.11% | 211 |
|
|
2025
Q2 | $438M | Buy |
1,341,694
+427,902
| +47% | +$118M | 0.07% | 334 |
|
|
2025
Q1 | $247M | Buy |
913,792
+355,302
| +64% | +$91.3M | 0.05% | 517 |
|
|
2024
Q4 | $131M | Sell |
558,490
-137,378
| -20% | -$36.1M | 0.02% | 732 |
|
|
2024
Q3 | $191M | Buy |
695,868
+303,027
| +77% | +$78.9M | 0.04% | 614 |
|
|
2024
Q2 | $95.5M | Buy |
392,841
+214,528
| +120% | +$33.9M | 0.02% | 802 |
|
|
2024
Q1 | $26.6M | Buy |
178,313
+1,453
| +0.8% | +$242K | 0.01% | 1306 |
|
|
2023
Q4 | $33.9M | Sell |
176,860
-39,709
| -18% | -$6.76M | 0.01% | 1176 |
|
|
2023
Q3 | $38.4M | Sell |
216,569
-173,558
| -44% | -$33.1M | 0.01% | 1064 |
|
|
2023
Q2 | $74.1M | Buy |
390,127
+22,752
| +6% | +$4.51M | 0.02% | 810 |
|
|
2023
Q1 | $73.6M | Sell |
367,375
-302,474
| -45% | -$63.6M | 0.02% | 812 |
|
|
2022
Q4 | $159M | Sell |
669,849
-67,981
| -9% | -$14.5M | 0.05% | 547 |
|
|
2022
Q3 | $148M | Buy |
737,830
+568,999
| +337% | +$109M | 0.05% | 521 |
|
|
2022
Q2 | $24.6M | Sell |
168,831
-799,924
| -83% | -$113M | 0.01% | 1247 |
|
|
2022
Q1 | $158M | Buy |
968,755
+78,665
| +9% | +$12M | 0.04% | 586 |
|
|
2021
Q4 | $151M | Sell |
890,090
-164,082
| -16% | -$30.5M | 0.04% | 625 |
|
|
2021
Q3 | $199M | Buy |
1,054,172
+52,271
| +5% | +$9.81M | 0.05% | 500 |
|
|
2021
Q2 | $170M | Sell |
1,001,901
-214,202
| -18% | -$31.4M | 0.04% | 608 |
|
|
2021
Q1 | $172M | Sell |
1,216,103
-62,139
| -5% | -$9.35M | 0.05% | 551 |
|
|
2020
Q4 | $166M | Buy |
1,278,242
+183,591
| +17% | +$24.5M | 0.05% | 514 |
|
|
2020
Q3 | $159M | Sell |
1,094,651
-30,044
| -3% | -$4.27M | 0.05% | 442 |
|
|
2020
Q2 | $167M | Buy |
1,124,695
+385,249
| +52% | +$51.9M | 0.06% | 396 |
|
|
2020
Q1 | $80.5M | Buy |
739,446
+161,316
| +28% | +$18.6M | 0.03% | 588 |
|
|
2019
Q4 | $66.6M | Buy |
578,130
+34,648
| +6% | +$3.45M | 0.02% | 864 |
|
|
2019
Q3 | $43.7M | Buy |
543,482
+46,934
| +9% | +$3.71M | 0.01% | 1056 |
|
|
2019
Q2 | $36M | Buy |
496,548
+289,314
| +140% | +$22.2M | 0.01% | 1165 |
|
|
2019
Q1 | $19.4M | Buy |
207,234
+189,786
| +1,088% | +$15.9M | 0.01% | 1249 |
|
|
2018
Q4 | $1.27M | Buy |
17,448
+2,940
| +20% | +$226K | ﹤0.01% | 2828 |
|
|
2018
Q3 | $1.27M | Sell |
14,508
-118,362
| -89% | -$11.9M | ﹤0.01% | 3018 |
|
|
2018
Q2 | $13.1M | Buy |
132,870
+77,140
| +138% | +$7.65M | ﹤0.01% | 1506 |
|
|
2018
Q1 | $6.64M | Sell |
55,730
-16,675
| -23% | -$2.15M | ﹤0.01% | 1785 |
|
|
2017
Q4 | $9.2M | Sell |
72,405
-8,473
| -10% | -$1.06M | ﹤0.01% | 1621 |
|
|
2017
Q3 | $9.5M | Buy |
80,878
+51,678
| +177% | +$4.41M | ﹤0.01% | 1596 |
|
|
2017
Q2 | $2.33M | Sell |
29,200
-140,948
| -83% | -$9.01M | ﹤0.01% | 2448 |
|
|
2017
Q1 | $8.72M | Buy |
170,148
+14,715
| +9% | +$680K | ﹤0.01% | 1627 |
|
|
2016
Q4 | $5.82M | Buy |
155,433
+41,667
| +37% | +$1.74M | ﹤0.01% | 1894 |
|
|
2016
Q3 | $7.71M | Buy |
113,766
+101,499
| +827% | +$7.16M | ﹤0.01% | 1674 |
|
|
2016
Q2 | $681K | Sell |
12,267
-118,168
| -91% | -$7.45M | ﹤0.01% | 3099 |
|
|
2016
Q1 | $8.19M | Sell |
130,435
-267,566
| -67% | -$17.8M | ﹤0.01% | 1522 |
|
|
2015
Q4 | $37.5M | Sell |
398,001
-135,504
| -25% | -$12.6M | 0.02% | 883 |
|
|
2015
Q3 | $42.9M | Sell |
533,505
-173,966
| -25% | -$19.3M | 0.02% | 811 |
|
|
2015
Q2 | $84.8M | Buy |
707,471
+177,724
| +34% | +$21.2M | 0.03% | 574 |
|
|
2015
Q1 | $55.3M | Buy |
529,747
+1,139
| +0.2% | +$115K | 0.02% | 760 |
|
|
2014
Q4 | $51.3M | Buy |
528,608
+12,628
| +2% | +$1.17M | 0.02% | 788 |
|
|
2014
Q3 | $40.3M | Buy |
515,980
+16,578
| +3% | +$1.07M | 0.02% | 895 |
|
|
2014
Q2 | $31.5M | Buy |
+499,402
| New | +$29.7M | 0.01% | 1023 |
|
|
2014
Q1 | – | Sell |
-381
| Closed | -$24K | – | 4090 |
|
|
2013
Q4 | $24K | Sell |
381
-56,130
| -99% | -$3.35M | ﹤0.01% | 4146 |
|
|
2013
Q3 | $3.62M | Sell |
56,511
-105,677
| -65% | -$5.27M | ﹤0.01% | 2143 |
|
|
2013
Q2 | $5.03M | Buy |
+162,188
| New | +$4.32M | ﹤0.01% | 1844 |
|
Other funds holding ALNY
Invesco's ALNY Position: Q2 2026 in Review
Invesco reduced its Alnylam Pharmaceuticals (ALNY) stake by 7.9% in Q2 2026, selling an estimated $96.8M and leaving 3,754,318 shares worth $1.13B. The position accounts for 0.09% of the portfolio, ranked #162.
Invesco first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.04B in Q4 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Invesco held 3,754,318 shares of Alnylam Pharmaceuticals worth $1.13B as of Q2 2026.
- Invesco sold 320,802 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $96.8M.
- Alnylam Pharmaceuticals made up 0.09% of Invesco's portfolio in Q2 2026, its #162 holding.
- Invesco first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Invesco's Alnylam Pharmaceuticals position peaked at $2.04B in Q4 2025.
- 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.